{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:24:05Z","timestamp":1792448645813,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpain.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pain"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jpain.2026.106277","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:01:13Z","timestamp":1774972873000},"page":"106277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Pharmacological inhibition of transforming growth factor-\u03b2 activated kinase 1 (TAK1) prevents chemotherapy induced peripheral neuropathy (CIPN)"],"prefix":"10.1016","volume":"43","author":[{"given":"Timothy","family":"Haystead","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Giuvelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Freeze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8128-8426","authenticated-orcid":false,"given":"Scott","family":"Scarneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpain.2026.106277_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1157306","article-title":"Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel","volume":"14","author":"Sousa-Pimenta","year":"2023","journal-title":"Front Pharm"},{"issue":"1","key":"10.1016\/j.jpain.2026.106277_bib2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s40001-024-01657-2","article-title":"Paclitaxel and its semi-synthetic derivatives: comprehensive insights into chemical structure, mechanisms of action, and anticancer properties","volume":"29","author":"Sati","year":"2024","journal-title":"Eur J Med Res"},{"issue":"4","key":"10.1016\/j.jpain.2026.106277_bib3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2174\/1568009033481912","article-title":"Paclitaxel (taxol) and taxoid derivates for lung cancer treatment: potential for aerosol delivery","volume":"3","author":"Gautam","year":"2003","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.jpain.2026.106277_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2019.113121","article-title":"Pathogenesis of paclitaxel-induced peripheral neuropathy: a current review of in vitro and in vivo findings using rodent and human model systems","volume":"324","author":"Staff","year":"2020","journal-title":"Exp Neurol"},{"issue":"10","key":"10.1016\/j.jpain.2026.106277_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/toxics9100229","article-title":"Pathomechanisms of paclitaxel-induced peripheral neuropathy","volume":"9","author":"Klein","year":"2021","journal-title":"Toxics"},{"issue":"5","key":"10.1016\/j.jpain.2026.106277_bib6","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/s41419-022-04964-w","article-title":"Paclitaxel binds and activates C5aR1: a new potential therapeutic target for the prevention of chemotherapy-induced peripheral neuropathy and hypersensitivity reactions","volume":"13","author":"Brandolini","year":"2022","journal-title":"Cell Death Dis"},{"issue":"5","key":"10.1016\/j.jpain.2026.106277_bib7","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2010-0248","article-title":"Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility","volume":"16","author":"Park","year":"2011","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.jpain.2026.106277_bib8","doi-asserted-by":"crossref","first-page":"516","DOI":"10.5603\/GP.2016.0036","article-title":"Chemotherapy-induced peripheral neuropathy \u2013 diagnosis, evolution and treatment","volume":"87","author":"Izycki","year":"2016","journal-title":"Ginekol Pol"},{"issue":"28","key":"10.1016\/j.jpain.2026.106277_bib9","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jpain.2026.106277_bib10","doi-asserted-by":"crossref","first-page":"200","DOI":"10.5603\/GP.a2018.0034","article-title":"Effectiveness of gabapentin pharmacotherapy in chemotherapy-induced peripheral neuropathy","volume":"89","author":"Magnowska","year":"2018","journal-title":"Ginekol Pol"},{"issue":"9","key":"10.1016\/j.jpain.2026.106277_bib11","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/cncr.23008","article-title":"Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3)","volume":"110","author":"Rao","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jpain.2026.106277_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2019.102831","article-title":"Prevention of chemotherapy-induced peripheral neuropathy: a review of recent findings","volume":"145","author":"Ibrahim","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jpain.2026.106277_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.12.006","article-title":"Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy","volume":"73","author":"Lees","year":"2017","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.jpain.2026.106277_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20122904","article-title":"Chemokine signaling in chemotherapy-induced neuropathic pain","volume":"20","author":"Brandolini","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.jpain.2026.106277_bib15","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/1521-4141(200108)31:8<2448::AID-IMMU2448>3.0.CO;2-N","article-title":"The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol","volume":"31","author":"Byrd-Leifer","year":"2001","journal-title":"Eur J Immunol"},{"issue":"7","key":"10.1016\/j.jpain.2026.106277_bib16","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jpain.2014.04.001","article-title":"Toll-like receptor 4 signaling contributes to paclitaxel-induced peripheral neuropathy","volume":"15","author":"Li","year":"2014","journal-title":"J Pain"},{"issue":"1","key":"10.1016\/j.jpain.2026.106277_bib17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12974-019-1619-9","article-title":"Paclitaxel-activated astrocytes produce mechanical allodynia in mice by releasing tumor necrosis factor-alpha and stromal-derived cell factor 1","volume":"16","author":"Liu","year":"2019","journal-title":"J Neuroinflamm"},{"issue":"4","key":"10.1016\/j.jpain.2026.106277_bib18","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/ejp.1169","article-title":"Blocking of cytokines signalling attenuates evoked and spontaneous neuropathic pain behaviours in the paclitaxel rat model of chemotherapy-induced neuropathy","volume":"22","author":"Al-Mazidi","year":"2018","journal-title":"Eur J Pain"},{"issue":"5","key":"10.1016\/j.jpain.2026.106277_bib19","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.bbi.2006.10.012","article-title":"Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats","volume":"21","author":"Ledeboer","year":"2007","journal-title":"Brain Behav Immun"},{"issue":"3","key":"10.1016\/j.jpain.2026.106277_bib20","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.cyto.2003.10.004","article-title":"Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy","volume":"25","author":"Pusztai","year":"2004","journal-title":"Cytokine"},{"issue":"9","key":"10.1016\/j.jpain.2026.106277_bib21","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.200099","article-title":"TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases","volume":"10","author":"Totzke","year":"2020","journal-title":"Open Biol"},{"issue":"6","key":"10.1016\/j.jpain.2026.106277_bib22","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1074\/jbc.RA119.011857","article-title":"A highly selective inhibitor of interleukin-1 receptor-associated kinases 1\/4 (IRAK-1\/4) delineates the distinct signaling roles of IRAK-1\/4 and the TAK1 kinase","volume":"295","author":"Scarneo","year":"2020","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.jpain.2026.106277_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-35189-7","article-title":"Genetic and pharmacological validation of TAK1 inhibition in macrophages as a therapeutic strategy to effectively inhibit TNF secretion","volume":"8","author":"Scarneo","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jpain.2026.106277_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpain.2023.04.011","article-title":"Transforming growth factor-beta-activated kinase 1 (TAK1) mediates chronic pain and cytokine production in mouse models of inflammatory, neuropathic, and primary pain","author":"Scarneo","year":"2023","journal-title":"J Pain"},{"issue":"3","key":"10.1016\/j.jpain.2026.106277_bib25","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1021\/acschembio.1c00788","article-title":"Development and efficacy of an orally bioavailable selective TAK1 inhibitor for the treatment of inflammatory arthritis","volume":"17","author":"Scarneo","year":"2022","journal-title":"ACS Chem Biol"},{"issue":"1","key":"10.1016\/j.jpain.2026.106277_bib26","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s13075-019-2073-x","article-title":"Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice","volume":"21","author":"Scarneo","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.jpain.2026.106277_bib27","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jpain.2023.04.011","article-title":"Transforming growth factor-beta-activated kinase 1 (TAK1) mediates chronic pain and cytokine production in mouse models of inflammatory, neuropathic, and primary pain","volume":"24","author":"Scarneo","year":"2023","journal-title":"J Pain"},{"issue":"14","key":"10.1016\/j.jpain.2026.106277_bib28","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.165358","article-title":"Pharmacological inhibition of TAK1 prevents and induces regression of experimental organ fibrosis","volume":"8","author":"Bale","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.jpain.2026.106277_bib29","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.2147\/JPR.S451409","article-title":"Transforming growth factor-beta-activated kinase 1 (TAK1) alleviates inflammatory joint pain in osteoarthritis and gouty arthritis preclinical models","volume":"17","author":"Freeze","year":"2024","journal-title":"J Pain Res"},{"issue":"1","key":"10.1016\/j.jpain.2026.106277_bib30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0165-0270(94)90144-9","article-title":"Quantitative assessment of tactile allodynia in the rat paw","volume":"53","author":"Chaplan","year":"1994","journal-title":"J Neurosci Methods"},{"issue":"6","key":"10.1016\/j.jpain.2026.106277_bib31","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nn.4549","article-title":"Identification of spinal circuits involved in touch-evoked dynamic mechanical pain","volume":"20","author":"Cheng","year":"2017","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.jpain.2026.106277_bib32","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.bbi.2015.06.003","article-title":"MAPK signaling downstream to TLR4 contributes to paclitaxel-induced peripheral neuropathy","volume":"49","author":"Li","year":"2015","journal-title":"Brain Behav Immun"},{"issue":"6","key":"10.1016\/j.jpain.2026.106277_bib33","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ana.24951","article-title":"Chemotherapy-induced peripheral neuropathy: a current review","volume":"81","author":"Staff","year":"2017","journal-title":"Ann Neurol"},{"issue":"39","key":"10.1016\/j.jpain.2026.106277_bib34","doi-asserted-by":"crossref","first-page":"13487","DOI":"10.1523\/JNEUROSCI.1956-15.2015","article-title":"The cancer chemotherapeutic paclitaxel increases human and rodent sensory neuron responses to TRPV1 by activation of TLR4","volume":"35","author":"Li","year":"2015","journal-title":"J Neurosci"},{"issue":"4","key":"10.1016\/j.jpain.2026.106277_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1124","article-title":"Delineation of the distinct inflammatory signaling roles of TAK1 and JAK1\/3 in the CIA model of rheumatoid arthritis","volume":"11","author":"Freeze","year":"2023","journal-title":"Pharm Res Perspect"},{"issue":"1","key":"10.1016\/j.jpain.2026.106277_bib36","first-page":"33","article-title":"Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer","volume":"30","author":"Teng","year":"2022","journal-title":"Support Care Cancer"},{"issue":"21","key":"10.1016\/j.jpain.2026.106277_bib37","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1016\/j.lfs.2004.01.007","article-title":"MAPK activation in nociceptive neurons and pain hypersensitivity","volume":"74","author":"Obata","year":"2004","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.jpain.2026.106277_bib38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.brainresrev.2008.12.011","article-title":"MAP kinase and pain","volume":"60","author":"Ji","year":"2009","journal-title":"Brain Res Rev"},{"issue":"4","key":"10.1016\/j.jpain.2026.106277_bib39","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1517\/14728222.9.4.699","article-title":"The ERK\/MAPK pathway, as a target for the treatment of neuropathic pain","volume":"9","author":"Ma","year":"2005","journal-title":"Expert Opin Ther Targets"},{"issue":"5","key":"10.1016\/j.jpain.2026.106277_bib40","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/j.pain.0000000000002454","article-title":"Dorsal root ganglion toll-like receptor 4 signaling contributes to oxaliplatin-induced peripheral neuropathy","volume":"163","author":"Illias","year":"2022","journal-title":"Pain"},{"key":"10.1016\/j.jpain.2026.106277_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112671","article-title":"Treatment and diagnosis of chemotherapy-induced peripheral neuropathy: an update","volume":"147","author":"Desforges","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"10.1016\/j.jpain.2026.106277_bib42","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/bja\/aex229","article-title":"Clinical and preclinical perspectives on chemotherapy-induced peripheral neuropathy (CIPN): a narrative review","volume":"119","author":"Flatters","year":"2017","journal-title":"Br J Anaesth"},{"issue":"11","key":"10.1016\/j.jpain.2026.106277_bib43","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.4049\/jimmunol.1001241","article-title":"Painful pathways induced by TLR stimulation of dorsal root ganglion neurons","volume":"186","author":"Qi","year":"2011","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.jpain.2026.106277_bib44","article-title":"Interactions of Notch1 and TLR4 signaling pathways in DRG neurons of in vivo and in vitro models of diabetic neuropathy","volume":"7","author":"Chen","year":"2017","journal-title":"Sci Rep"}],"container-title":["The Journal of Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526590026000957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526590026000957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:57:13Z","timestamp":1783929433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526590026000957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":44,"alternative-id":["S1526590026000957"],"URL":"https:\/\/doi.org\/10.1016\/j.jpain.2026.106277","relation":{},"ISSN":["1526-5900"],"issn-type":[{"value":"1526-5900","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological inhibition of transforming growth factor-\u03b2 activated kinase 1 (TAK1) prevents chemotherapy induced peripheral neuropathy (CIPN)","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pain","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpain.2026.106277","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of United States Association for the Study of Pain, Inc","name":"copyright","label":"Copyright"}],"article-number":"106277"}}